BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36084807)

  • 1. An artificial intelligence model to predict survival and chemotherapy benefits for gastric cancer patients after gastrectomy development and validation in international multicenter cohorts.
    Li X; Zhai Z; Ding W; Chen L; Zhao Y; Xiong W; Zhang Y; Lin D; Chen Z; Wang W; Gao Y; Cai S; Yu J; Zhang X; Liu H; Li G; Chen T
    Int J Surg; 2022 Sep; 105():106889. PubMed ID: 36084807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit.
    Jiang Y; Xie J; Han Z; Liu W; Xi S; Huang L; Huang W; Lin T; Zhao L; Hu Y; Yu J; Zhang Q; Li T; Cai S; Li G
    Clin Cancer Res; 2018 Nov; 24(22):5574-5584. PubMed ID: 30042208
    [No Abstract]   [Full Text] [Related]  

  • 3. Association of Tumor-Associated Collagen Signature With Prognosis and Adjuvant Chemotherapy Benefits in Patients With Gastric Cancer.
    Chen D; Chen H; Chi L; Fu M; Wang G; Wu Z; Xu S; Sun C; Xu X; Lin L; Cheng J; Jiang W; Dong X; Lu J; Zheng J; Chen G; Li G; Zhuo S; Yan J
    JAMA Netw Open; 2021 Nov; 4(11):e2136388. PubMed ID: 34846524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An artificial intelligence method to assess the tumor microenvironment with treatment outcomes for gastric cancer patients after gastrectomy.
    Chen T; Li X; Mao Q; Wang Y; Li H; Wang C; Shen Y; Guo E; He Q; Tian J; Zhu M; Wu J; Liang W; Liu H; Yu J; Li G
    J Transl Med; 2022 Feb; 20(1):100. PubMed ID: 35189890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A commentary on "An artificial intelligence model to predict survival and chemotherapy benefits for gastric cancer patients after gastrectomy development and validation in international multicenter cohorts".
    Liu ZP; Dai HS; Zhang YQ; Yin XY; Chen ZY
    Int J Surg; 2023 Jan; 109(1):1-2. PubMed ID: 36799779
    [No Abstract]   [Full Text] [Related]  

  • 6. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
    Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
    Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy.
    Qian J; Qian Y; Wang J; Gu B; Pei D; He S; Zhu F; Røe OD; Xu J; Liu L; Gu Y; Guo R; Yin Y; Shu Y; Chen X
    Drug Des Devel Ther; 2016; 10():241-58. PubMed ID: 26966350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
    Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
    [No Abstract]   [Full Text] [Related]  

  • 9. An Immune Cell Signature Is Associated With Disease-Free Survival and Adjuvant Chemosensitivity of Patients With Resectable Gastric Cancer.
    Yan H; Chen Y; Yang Z; Li Z; Che X; Xiao J; Liu Y; Qu X
    Front Immunol; 2020; 11():621623. PubMed ID: 33613554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Immune Microenvironment and Chemosensitivity Signature for Predicting Response to Chemotherapy in Gastric Cancer.
    Jiang Y; Xie J; Huang W; Chen H; Xi S; Han Z; Huang L; Lin T; Zhao LY; Hu YF; Yu J; Cai SR; Li T; Li G
    Cancer Immunol Res; 2019 Dec; 7(12):2065-2073. PubMed ID: 31615816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-adjuvant chemotherapy leukocyte count may predict the outcome for advanced gastric cancer after radical resection.
    Pei D; Zhu F; Chen X; Qian J; He S; Qian Y; Shen H; Liu Y; Xu J; Shu Y
    Biomed Pharmacother; 2014 Mar; 68(2):213-7. PubMed ID: 24581723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center.
    Kano Y; Ohashi M; Hiki N; Takahari D; Chin K; Yamaguchi K; Tsuda Y; Shoji Y; Yasufuku I; Eto K; Ida S; Kumagai K; Nunobe S; Sano T
    Gastric Cancer; 2018 Nov; 21(6):1024-1030. PubMed ID: 29700635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival analysis of elderly patients over 65 years old with stage II/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study.
    Liang Y; Zhao L; Chen H; Lin T; Chen T; Zhao M; Hu Y; Yu J; Liu H; Li G
    BMC Cancer; 2021 Feb; 21(1):196. PubMed ID: 33632161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison between gastric and esophageal classification system among adenocarcinomas of esophagogastric junction according to AJCC 8th edition: a retrospective observational study from two high-volume institutions in China.
    Liu K; Feng F; Chen XZ; Zhou XY; Zhang JY; Chen XL; Zhang WH; Yang K; Zhang B; Zhang HW; Zhou ZG; Hu JK
    Gastric Cancer; 2019 May; 22(3):506-517. PubMed ID: 30390154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.
    Li H; Lin D; Yu Z; Li H; Zhao S; Hainisayimu T; Liu L; Wang K
    Front Immunol; 2022; 13():947802. PubMed ID: 36405735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indications for Adjuvant Chemotherapy in Stage II Gastric Cancer After D2 Gastrectomy-A Chinese Multicenter Study.
    Deng ZJ; Lu J; Nie RC; Fang JM; Chen XJ; Liu JJ; Li XZ; Chen YB; Huang CM; Lian L; Peng JS; Chen S
    Ann Surg Oncol; 2022 Dec; 29(13):8214-8224. PubMed ID: 35798893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of an artificial neural network for predicting the potential chemotherapy benefit of patients with gastric cancer after radical surgery.
    Lu J; Xue Z; Xu BB; Wu D; Zheng HL; Xie JW; Wang JB; Lin JX; Chen QY; Li P; Huang CM; Zheng CH
    Surgery; 2022 Apr; 171(4):955-965. PubMed ID: 34756492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant treatment combining cellular immunotherapy with chemotherapy improves the clinical outcome of patients with stage II/III gastric cancer.
    Wang Y; Wang C; Xiao H; Niu C; Wu H; Jin H; Yao C; He H; Tian H; Han F; Li D; Han W; Xu J; Chen J; Cui J; Li W
    Cancer Med; 2017 Jan; 6(1):45-53. PubMed ID: 27790867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The value of spleen density in predicting prognosis of patients with gastric cancer after curative gastrectomy].
    Li S; Ma PF; Zhang JL; Cao YH; Liu CY; Zhang XJ; Li ZY; Xue YW; Zhao YZ
    Zhonghua Yi Xue Za Zhi; 2021 Sep; 101(34):2703-2709. PubMed ID: 34510877
    [No Abstract]   [Full Text] [Related]  

  • 20. Development and Validation of a Deep Learning CT Signature to Predict Survival and Chemotherapy Benefit in Gastric Cancer: A Multicenter, Retrospective Study.
    Jiang Y; Jin C; Yu H; Wu J; Chen C; Yuan Q; Huang W; Hu Y; Xu Y; Zhou Z; Fisher GA; Li G; Li R
    Ann Surg; 2021 Dec; 274(6):e1153-e1161. PubMed ID: 31913871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.